166 related articles for article (PubMed ID: 31677447)
1. Synthesis and biological evaluation of new MET inhibitors with 1,6-naphthyridinone scaffold.
Wang MS; Zhuo LS; Yang FP; Wang WJ; Huang W; Yang GF
Eur J Med Chem; 2020 Jan; 185():111803. PubMed ID: 31677447
[TBL] [Abstract][Full Text] [Related]
2. 2,7-naphthyridinone-based MET kinase inhibitors: A promising novel scaffold for antitumor drug development.
Zhuo LS; Xu HC; Wang MS; Zhao XE; Ming ZH; Zhu XL; Huang W; Yang GF
Eur J Med Chem; 2019 Sep; 178():705-714. PubMed ID: 31229873
[TBL] [Abstract][Full Text] [Related]
3. Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2.
Xu H; Wang M; Wu F; Zhuo L; Huang W; She N
Bioorg Med Chem; 2020 Jun; 28(12):115555. PubMed ID: 32503697
[TBL] [Abstract][Full Text] [Related]
4. Discovery of 1,6-naphthyridinone-based MET kinase inhibitor bearing quinoline moiety as promising antitumor drug candidate.
Chen T; Zhuo LS; Liu PF; Fang WR; Li YM; Huang W
Eur J Med Chem; 2020 Apr; 192():112174. PubMed ID: 32113049
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of novel 4-phenoxy-6,7-disubstituted quinolines possessing (thio)semicarbazones as c-Met kinase inhibitors.
Zhai X; Bao G; Wang L; Cheng M; Zhao M; Zhao S; Zhou H; Gong P
Bioorg Med Chem; 2016 Mar; 24(6):1331-45. PubMed ID: 26897090
[TBL] [Abstract][Full Text] [Related]
6. Discovery of quinazolin-4-amines bearing benzimidazole fragments as dual inhibitors of c-Met and VEGFR-2.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Bioorg Med Chem; 2014 Sep; 22(17):4735-44. PubMed ID: 25082515
[TBL] [Abstract][Full Text] [Related]
7. Exploration of novel pyrrolo[2,1-f][1,2,4]triazine derivatives with improved anticancer efficacy as dual inhibitors of c-Met/VEGFR-2.
Shi W; Qiang H; Huang D; Bi X; Huang W; Qian H
Eur J Med Chem; 2018 Oct; 158():814-831. PubMed ID: 30248654
[TBL] [Abstract][Full Text] [Related]
8. Molecular docking simulation, synthesis and 3D pharmacophore studies of novel 2-substituted-5-nitro-benzimidazole derivatives as anticancer agents targeting VEGFR-2 and c-Met.
Ibrahim HA; Awadallah FM; Refaat HM; Amin KM
Bioorg Chem; 2018 Apr; 77():457-470. PubMed ID: 29453077
[No Abstract] [Full Text] [Related]
9. Design and synthesis of novel substituted naphthyridines as potential c-Met kinase inhibitors based on MK-2461.
Wu JF; Liu MM; Huang SX; Wang Y
Bioorg Med Chem Lett; 2015 Aug; 25(16):3251-5. PubMed ID: 26077488
[TBL] [Abstract][Full Text] [Related]
10. Investigation on the 1,6-naphthyridine motif: discovery and SAR study of 1H-imidazo[4,5-h][1,6]naphthyridin-2(3H)-one-based c-Met kinase inhibitors.
Wang Y; Xu ZL; Ai J; Peng X; Lin JP; Ji YC; Geng MY; Long YQ
Org Biomol Chem; 2013 Mar; 11(9):1545-62. PubMed ID: 23188156
[TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and biological evaluation of novel N-sulfonylamidine-based derivatives as c-Met inhibitors via Cu-catalyzed three-component reaction.
Nan X; Zhang J; Li HJ; Wu R; Fang SB; Zhang ZZ; Wu YC
Eur J Med Chem; 2020 Aug; 200():112470. PubMed ID: 32505087
[TBL] [Abstract][Full Text] [Related]
12. Discovery of 8-Amino-Substituted 2-Phenyl-2,7-Naphthyridinone Derivatives as New c-Kit/VEGFR-2 Kinase Inhibitors.
Sun H; Zhuo L; Dong H; Huang W; She N
Molecules; 2019 Dec; 24(24):. PubMed ID: 31817456
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel pyrrolo-pyridine/pyrimidine derivatives bearing pyridazinone moiety as c-Met kinase inhibitors.
Wang LX; Liu X; Xu S; Tang Q; Duan Y; Xiao Z; Zhi J; Jiang L; Zheng P; Zhu W
Eur J Med Chem; 2017 Dec; 141():538-551. PubMed ID: 29107421
[TBL] [Abstract][Full Text] [Related]
14. Structure-based design, synthesis, and evaluation of imidazo[1,2-b]pyridazine and imidazo[1,2-a]pyridine derivatives as novel dual c-Met and VEGFR2 kinase inhibitors.
Matsumoto S; Miyamoto N; Hirayama T; Oki H; Okada K; Tawada M; Iwata H; Nakamura K; Yamasaki S; Miki H; Hori A; Imamura S
Bioorg Med Chem; 2013 Dec; 21(24):7686-98. PubMed ID: 24216091
[TBL] [Abstract][Full Text] [Related]
15. Discovery of novel 2-substituted-4-(2-fluorophenoxy) pyridine derivatives possessing pyrazolone and triazole moieties as dual c-Met/VEGFR-2 receptor tyrosine kinase inhibitors.
Gu W; Dai Y; Qiang H; Shi W; Liao C; Zhao F; Huang W; Qian H
Bioorg Chem; 2017 Jun; 72():116-122. PubMed ID: 28411406
[TBL] [Abstract][Full Text] [Related]
16. Structure-activity relationship study of novel quinazoline-based 1,6-naphthyridinones as MET inhibitors with potent antitumor efficacy.
Zhuo LS; Wu FX; Wang MS; Xu HC; Yang FP; Tian YG; Zhao XE; Ming ZH; Zhu XL; Hao GF; Huang W
Eur J Med Chem; 2020 Dec; 208():112785. PubMed ID: 32898795
[TBL] [Abstract][Full Text] [Related]
17. Discovery of N-(2-phenyl-1H-benzo[d]imidazol-5-yl)quinolin-4-amine derivatives as novel VEGFR-2 kinase inhibitors.
Shi L; Wu TT; Wang Z; Xue JY; Xu YG
Eur J Med Chem; 2014 Sep; 84():698-707. PubMed ID: 25064347
[TBL] [Abstract][Full Text] [Related]
18. Design, Synthesis, In Vitro Anti-cancer Activity, ADMET Profile and Molecular Docking of Novel Triazolo[3,4-a]phthalazine Derivatives Targeting VEGFR-2 Enzyme.
El-Helby AA; Sakr H; Ayyad RRA; El-Adl K; Ali MM; Khedr F
Anticancer Agents Med Chem; 2018; 18(8):1184-1196. PubMed ID: 29651967
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel 2-aminopyridine-3-carboxamides as c-Met kinase inhibitors.
Zhang D; Ai J; Liang Z; Li C; Peng X; Ji Y; Jiang H; Geng M; Luo C; Liu H
Bioorg Med Chem; 2012 Sep; 20(17):5169-80. PubMed ID: 22863529
[TBL] [Abstract][Full Text] [Related]
20. Transforming Type II to Type I c-Met kinase inhibitors via combined scaffold hopping and structure-guided synthesis of new series of 1,3,4-thiadiazolo[2,3-c]-1,2,4-triazin-4-one derivatives.
El-Wakil MH; Teleb M
Bioorg Chem; 2021 Nov; 116():105304. PubMed ID: 34534756
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
